Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
KENALOG IN ORABASE vs NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Category C
Category D/X
Corticosteroid
Corticosteroid